IL-33 Improves Glucose-Lipid Metabolism Disorders in ob/ob Mice
LU Jing-li1,2, GUO Xiao-li3, LIANG Yan1,2, ZHAO Jun-jie1,2, MENG Hai-yang1,2
1. Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; 2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou 450052, China; 3. Department of Gynaecology and Obstetrics, Renmin Hospital of Shayang, Jingmen 448200, China
Abstract：OBJECTIVE To investigate the effects of cytokine IL-33 on glucose-lipid metabolism disorder and its underlying mechanism. METHODS Ob/ob mice were injected for 4 weeks with IL-33 (0.5 μg·mice-1, every other day) or PBS. Body weight and blood glucose were measured weekly. After two weeks, glucose tolerance tests were performed. After administration, histological analyses for liver, fat and pancreatic tissues were performed. The mRNA expression of inflammatory factors in fat tissues, Cd73 and Cd39 in splenic lymphocytes, as well as protein expression of nuclear receptors in liver tissues were detected. RESULTS The results showed that IL-33 decreased body weight and blood glucose, improved glucose tolerance, and reduced serum triglyceride in ob/ob mice. IL-33 reduced lipid accumulation in liver tissues, decreased adipocyte size, and maintained the islet morphology and structural integrity. IL-33 decreased the mRNA expression of Ccl2 and Il1a, whereas increased the expression of Cd73 and Cd39. Further analysis revealed that IL-33 increased expression of nuclear receptors LXR and PPARγ. CONCLUSION The effect of IL-33 on inflammatory response and nuclear receptors might contribute to the improvement of glucose-lipid metabolism in ob/ob mice.
CAYROL C, GIRARD J P. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev, 2018, 281(1):154-168.
[2]
GRIESENAUER B, PACZESNY S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol, 2017, 8:475.
[3]
PEINE M, MAREK R M, LOHNING M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol, 2016, 37(5):321-333.
[4]
LU J, KANG J, ZHANG C, et al. The role of IL-33/ST2L signals in the immune cells. Immunol Lett, 2015, 164(1):11-17.
[5]
SALTIEL A R, OLEFSKY J M. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest, 2017, 127(1):1-4.
[6]
MCLAUGHLIN T, ACKERMAN S E, SHEN L, et al. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest, 2017, 127(1):5-13.
[7]
CHEN X, YANG L, DU G. Research progress of urotensin Ⅱ on energy metabolism in type 2 diabetes. Chin Pharm J(中国药学杂志), 2018, 53(22):1885-1889.
[8]
DE OLIVEIRA M F A, TALVANI A, ROCHA-VIEIRA E. IL-33 in obesity: where do we go from here?. Inflamm Res, 2019, 68(3):185-194.
[9]
LU J, LIANG Y, ZHAO J, et al. Interleukin-33 prevents the development of autoimmune diabetes in NOD mice. Int Immunopharmacol, 2019, 70:9-15.
[10]
ODEGAARD J I, LEE M W, SOGAWA Y, et al. Perinatal licensing of thermogenesis by IL-33 and ST2. Cell, 2016, 166(4):841-854.
[11]
CIPOLLETTA D, FEUERER M, LI A, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature, 2012, 486(7404):549-553.
[12]
HAN J M, WU D, DENROCHE H C, et al. IL-33 reverses an obesity-induced deficit in visceral adipose tissue ST2+ T regulatory cells and ameliorates adipose tissue inflammation and insulin resistance. J Immunol, 2015, 194(10):4777-4783.
[13]
GROSS B, PAWLAK M, LEFEBVRE P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol, 2017, 13(1):36-49.
[14]
MARCIANO D P, CHANG M R, CORZO C A, et al. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. Cell Metab, 2014, 19(2):193-208.
[15]
GRINBERG-BLEYER Y, BAEYENS A, YOU S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med, 2010, 207(9):1871-1878.
[16]
ROSENZWAJG M, LORENZON R, CACOUB P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis, 2019, 78(2):209-217.
[17]
MILLER A M, ASQUITH D L, HUEBER A J, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res, 2010, 107(5):650-658.
[18]
DALMAS E, LEHMANN F M, DROR E, et al. Interleukin-33-activated islet-resident innate lymphoid cells promote insulin secretion through myeloid cell retinoic acid production. Immunity, 2017, 47(5):928-942.
[19]
VIJAYAN D, YOUNG A, TENG M W L, et al. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer, 2017, 17(12):765.
[20]
SAUER A V, BRIGIDA I, CARRIGLIO N, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood, 2012, 119(6):1428-1439.
[21]
PETERSEN M C, SHULMAN G I. Mechanisms of insulin action and insulin resistance. Phys Rev, 2018, 98(4):2133-2223.
[22]
LIN C Y, GUSTAFSSON J A. Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer, 2015, 15(4):216-224.
[23]
LOU X, TORESSON G, BENOD C, et al. Structure of the retinoid X receptor alpha-liver X receptor beta (RXRalpha-LXRbeta) heterodimer on DNA. Nat Struct Mol Biol, 2014, 21(3):277-281.
[24]
LAFFITTE B A, CHAO L C, LI J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA, 2003, 100(9):5419-5424.
[25]
SCHULMAN I G. Liver X receptors link lipid metabolism and inflammation. FEBS Lett, 2017, 591(19):2978-2991.
[26]
HUANG W, GLASS C K. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol, 2010, 30(8):1542-1549.
2020, Vol. 55 
